



31st Annual

- Cardiology for the Practitioner -

May 2nd, 2020


- All attendees are in listen only mode to minimize background noise
- Click on the arrow to expand the audio pane
- You have an option to connect through your computer audio (VOIP) – default option after you join the webinar **OR**
- By phone, if you wish to connect by phone - select the “Phone call” option –
 1. Dial the Toll-free number
 2. enter the access code followed by the # key and
 3. enter your unique audio pin followed by the # key.



Housekeeping Notes

Questions for the Faculty

- A five-minute q&a has been designated after each presentation
- You may submit your question(s) for a speaker through the question pane in the control panel at any time during the presentation – we will collect the questions and address them during the Q&A timeslots
- If you have a question for a specific member of the faculty, we recommend that you include the faculty name e.g. This question is for Dr. Anatoly Langer
- You may also raise your hand for your line to be unmuted. This option will be available during the Q&A timeslots



In the event that we do not have the time to address all the submitted questions during the time allotted to the Q&A during the webinar, we ask that you visit the meeting website within a few days after the webinar.

You will be able to view the responses to all of your questions as well as access the program materials and evaluation form.

www.chrc.net/smh

8:30	Welcome and Introduction	Howard Leong-Poi, MD
Session I: Risk Factor Control		
8:40	Guidelines for Lipid Lowering: Canadian, eh?	Beth Abramson, MD
9:05	Controversies in dyslipidemia management	Ronald Goldenberg, MD
9:30	Diabetes management: focusing on CV outcomes	Kim Connelly, MD
9:55	Management of HFrEF: the old and the new	Gordon Moe, MD
Session II: Updates in Common Cardiovascular Problems		
10:20	Antithrombotic therapy in primary and secondary prevention	John Graham, MD
10:45	The changing landscape of secondary prevention	David Fitchett, MD
11:10	Best approach in patients with ISCHEMIA	Shaun Goodman, MD
11:35	CAD + AF: Difficult decisions when two diseases co-exist	Akshay Bagai, MD
Session III: Innovations and New Approaches for Your Patients		
12:00	Looking for AF in all the right places	Kamran Ahmad, MD
12:25	New clinical trials that impact on your practice	Andrew Yan, MD
12:50	When the art of medicine is in the way of the practice of medicine	Anatoly Langer, MD
13:15	Show and tell: clinical vignettes (primary PCI, PCI vs CABG, TAVI)	Yin Ge, MD
13:40	CONCLUSION	

Upon completion of this activity, participants will have increased ability to:

1. Recognize the risks and benefits of various therapeutic options in managing patients with CAD.
2. Implement strategies for managing patients with complex cardiovascular disease and risk factors, including patients with atrial fibrillation, hypertension, diabetes and heart failure.
3. Implement strategies for appropriate stroke prevention in patients with atrial fibrillation.
4. Evaluate efficacy of antiplatelet therapies in preventing adverse cardiovascular outcomes.
5. Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
6. Recognize patients with complex problems that require comprehensive assessment and how to assess the optimal approach to patient management.

College of Family Physicians of Canada – Mainpro+:

This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Faculty of Medicine, University of Toronto for up to 6.0 Mainpro+ credits.

Royal College of Physicians and Surgeons of Canada – Section 1:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Faculty of Medicine, University of Toronto. You may claim a maximum of 6.0 hours (credits are automatically calculated).

- A link to the evaluation form for this program will be emailed to you at the conclusion of the sessions and will also be available at www.chrc.net/smh
- Participants that complete and submit the evaluation form will be emailed the Certificate of Participation

This program has received an educational grant or in-kind support from:

GOLD



Bayer HealthCare



Bristol-Myers Squibb



BRONZE

AMGEN[®]



Boehringer
Ingelheim



HLS Therapeutics



novo nordisk[®]

Dr. Howard Leong-Poi

Welcome and Introduction

Relationships with commercial interests:

- Grants/Research Support: N/A
- Speakers Bureau/Honoraria: Lantheus Medical Imaging, Janssen Canada
- Consulting Fees: N/A
- Patents: N/A
- Other: N/A

This program has received financial support from Amgen, Bayer, Bristol Myers Squibb/Pfizer, HLS Therapeutics and Novo Nordisk in the form of an educational grant.

This program has received no external in-kind support.

Potential for conflict(s) of interest:

- Dr's Abramson, Ahmad, Bagai, Connelly, Fitchett, Ge, Goldenberg, Goodman, Graham, Langer, Leong-Poi, Moe, Yan, have received (grant/research support, honoraria and consulting fees) from the organizations supporting this program and/or organizations whose product(s) are being discussed in this program.
 - Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, and Valeant developed/licenses/distributes/benefits from the sale of, etc. a product that will be discussed in this program.



Dr's Abramson, Ahmad, Bagai, Connelly, Fitchett, Ge, Goldenberg, Goodman, Graham, Langer, Leong-Poi, Moe, Yan

Amgen	Boehringer Ingelheim	Janssen	Novartis	Sanofi
Evolocumab (Repatha™)	Dabigatran (Pradaxa®) Linagliptin (Tradjenta®) Telmisartan (Micardis®) Telmisartan/Amlodipine (Twynstra™)	Canagliflozin (Invokana™)	Aliskiren / hydrochlorothiazide (Rasilez®/Rasilez-HCT®) Benazepril (Lotensin®) Fluvastatin (Lescol® / Lescol XL®) Metoprolol (Lopresor® / Lopresor SR®) Nateglinide (Starlix®) Pindolol / hydrochlorothiazide (Visken®, Viskazide®) Valsartan (Diovan®) Entresto® (sacubitril/valsartan)	Alirocumab (Praluent™) Clopidogrel (Plavix®) Glargine (Lantus®) Ramipril (Altace®) Sulfonylurea (Amaryl®)
AstraZeneca	Bristol Myers Squibb	HLS Therapeutics	Novo Nordisk	Servier
Rosuvastatin (Crestor®) Saxagliptin (Onglyza®) Saxagliptin (Onglyza™) Ticagrelor (Brilinta®)	Apixaban (Eliquis®) Clopidogrel (Plavix®) Exenitide (Byetta®) Metformin hydrochloride / Metformin hydrochloride and Glyburide (Glucophage®) Glucophage® XR Extended Release, Glucovance® Saxagliptin (Onglyza®) Warfarin (Coumadin®)	Icosapent Ethyl (Vascepa®)	Repaglinide (GlucoNorm®) Insulins (Novolin® GE, Novolin® GE NPH, NovoMix® 30, Novolin® GE 30/70, 40/60, 50/50) Liraglutide (Victoza®) Tresiba® (insulin degludec injection) Fiasp® (insulin aspart injection) Ozempic® (semaglutide injection)	Glucalazide (Diamicon®) Ivabradine (Procoralan®) Perindopril (Coversyl®)
Bayer	Eli Lilly	Merck	Pfizer	Takeda
Acarbose (Glucobay™) Aspirin™ Nifedipine (Adalat XL®, Adalat®XL® PLUS) Rivaroxaban (Xarelto®)	Linagliptin (Tradjenta®) Prasugrel (Effient®)	Ezetimibe (Ezetrol®) Olmesartan Medoxomil (Olmetec®) Simvastatin (Zocor®) Sitagliptin (Januvia®) Sitagliptin/Metformin (Janumet™)	Amlodipine (Norvasc®) Apixaban (Eliquis®) Atorvastatin (Lipitor®) Gemfibrozil (Lopid®) Quinapril Hydrochloride (Accupril™) Quinapril Hydrochloride and Hydrochlorothiazide (Accuretic®)	Azilsartan medoxomil /chlorthalidone (Edarbi®/Edarbyclor™) Pioglitazone (Actos®) Valeant Metformin Hydrochloride (Glumetza®(SB)) Metformin Hydrochloride (Glycon®) Colesevelam Hydrochloride (Lodalis™)

8:30 am Welcome and Introduction

Howard Leong-Poi, MD

Session I: **Risk Factor Control**

8:40 am Guidelines for lipid lowering: Canadian eh?
Interactive Q&A

Beth Abramson, MD

9:05 Controversies in dyslipidemia management
Interactive Q&A

Ronald Goldenberg, MD

9:30 Diabetes management: focusing on CV outcomes
Interactive Q&A

Kim Connelly, MD

9:55 Management of HFrEF: the old and the new
Interactive Q&A

Gordon Moe, MD

Session II: **Updates in Common Cardiovascular Problems**

10:20 am	Antithrombotic therapy in primary and secondary prevention Interactive Q&A	<i>John Graham, MD</i>
10:45	The changing landscape of secondary prevention Interactive Q&A	<i>David Fitchett, MD</i>
11:10	Best approach in patient with ISCHEMIA Interactive Q&A	<i>Shaun Goodman, MD</i>
11:35	CAD + AF: Difficult decisions when two diseases co-exist Interactive Q&A	<i>Akshay Bagai, MD</i>

Session III: **Innovations and New Approaches for Your Patients**

12:00 pm	Looking for AF in all the right places Interactive Q&A	<i>Kamran Ahmad, MD</i>
12:25	New Clinical Trials that Impact on Your Practice Interactive Q&A	<i>Andrew Yan, MD</i>
12:50	When the art of medicine is in the way of practice of medicine Interactive Q&A	<i>Anatoly Langer, MD</i>
1:15	Show and tell: clinical vignettes (primary PCI, PCI vs CABG, TAVI) Interactive Q&A	<i>Yin Ge, MD</i>
1:40 pm	Conclusion	